Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies
July 31, 2024 07:00 ET
|
Umoja Biopharma, Inc.
- UB-VV111 is potentially the first in situ generated CD19 chimeric antigen receptor (CAR)-T cell therapy to be evaluated in humans in the hematology setting - - First patient expected to be dosed by...
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
June 13, 2024 08:00 ET
|
Umoja Biopharma, Inc.
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
Umoja Biopharma to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 19, 2024 08:30 ET
|
Umoja Biopharma, Inc.
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer
February 28, 2024 08:30 ET
|
Umoja Biopharma, Inc.
SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma to Participate in a Fireside Chat at the Evercore ISI 2024 Emerging Biotech Conference
February 22, 2024 08:30 ET
|
Umoja Biopharma, Inc.
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 08:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T...
Umoja Biopharma Presents Preclinical Data at the 65th American Society of Hematology Annual Meeting Demonstrating In Vivo CAR T Cell Generation with Potent and Highly Durable Activity
December 11, 2023 13:30 ET
|
Umoja Biopharma, Inc.
Durable B cell aplasia up to 76 days observed in non-human primates following a single dose of VivoVec™ particles without lymphodepletion, exceeding industry benchmarks for ex vivo CAR T cell...
Umoja Biopharma Announces Oral Presentation at the 65th American Society of Hematology Annual Meeting
November 02, 2023 09:43 ET
|
Umoja Biopharma, Inc.
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced that...
Umoja Biopharma Announces Opening of Development and Manufacturing Facility in Louisville, Colorado
October 19, 2023 10:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, announced today the...
Umoja Biopharma to Present at the 2023 Cell & Gene Meeting on the Mesa
October 05, 2023 14:30 ET
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced that...